Favorable Safety Profile
Preclinical studies have shown VE3 to be well-tolerated, with no significant toxicity observed in animal models, supporting its advancement to clinical
Combination Synergy
VE3 works seamlessly with existing standard-of-care therapies, enhancing their effectiveness and overcoming resistance in advanced cancers.
Metastasis Prevention
Reduces the spread of secondary tumors by targeting ALDH1A3-expressing cancer stem cells, a key driver of metastasis in aggressive cancers.
High Potency and Specificity
Demonstrates nanomolar-level potency in preclinical studies, making it one of the most effective inhibitors of its kind.
Exceptional specificity minim
Targeted Action
VE3 directly inhibits ALDH1A3, a protein linked to tumor growth, metastasis, and chemotherapy resistance, ensuring precise targeting of cancer cells wi
Combination Therapy
Enhancing the effectiveness of standard-of-care treatments by integrating ALDH1A3 inhibitors for synergistic outcomes.
Pancreatic Cancer
Aiming to provide new therapeutic options for one of the most challenging cancers to treat due to its resistance to conventional therapies.
Glioblastoma
Developing innovative treatments for this aggressive brain cancer, with a focus on limiting tumor growth and improving quality of life.